ClinicalTrials.gov
ClinicalTrials.gov Menu

Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) (OPUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00125034
Recruitment Status : Completed
First Posted : July 29, 2005
Results First Posted : October 4, 2011
Last Update Posted : August 7, 2014
Sponsor:
Information provided by (Responsible Party):
Merck KGaA

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Neoplasm Metastasis
Colorectal Cancer
Interventions: Biological: Cetuximab
Drug: Oxaliplatin

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
First & last subject randomized: 27 Jul 2005 & 8 Mar 2006, respectively. Primary outcome and disease control rate cut-off dates 4 Aug 2006, others: 1 Mar 2007; except overall survival, KRAS overall survival and KRAS progression-free survival outcomes, metastatic surgery outcome and adverse events: 30 Nov 2008.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
629 subjects were prescreened, of whom 344 subjects were randomised. 338 subjects (Safety Population) received treatment. One subject was erroneously randomized, and was excluded from the ITT population (337 subjects).

Reporting Groups
  Description
Cetuximab Plus FOLFOX-4 Cetuximab plus 5-Fluorouracil(5-FU)/Folinic acid (FA) and oxaliplatin. Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin FA will be administered (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks). Until progression or unacceptable toxicity develops. Safety population: includes all treated subjects.
FOLFOX-4 Alone 5-FU/FA and oxaliplatin. Oxaliplatin will always be administered first or simultaneously with FA (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m^2/day IV over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks). Until progression or unacceptable toxicity develops. Safety population: includes all treated subjects.

Participant Flow:   Overall Study
    Cetuximab Plus FOLFOX-4   FOLFOX-4 Alone
STARTED   170 [1]   168 [2] 
COMPLETED   170   168 
NOT COMPLETED   0   0 
[1] Randomized & treated. 1 subject was not randomized correctly and was excluded in the ITT population.
[2] Randomized & treated



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Cetuximab Plus FOLFOX-4 Cetuximab plus 5-Fluorouracil(5-FU)/Folinic acid (FA) and oxaliplatin. Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin FA will be administered (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks). Until progression or unacceptable toxicity develops. Safety population: includes all treated subjects.
FOLFOX-4 Alone 5-FU/FA and oxaliplatin. Oxaliplatin will always be administered first or simultaneously with FA (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m^2/day IV over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks). Until progression or unacceptable toxicity develops. Safety population: includes all treated subjects.
Total Total of all reporting groups

Baseline Measures
   Cetuximab Plus FOLFOX-4   FOLFOX-4 Alone   Total 
Overall Participants Analyzed 
[Units: Participants]
 169   168   337 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   96   109   205 
>=65 years   73   59   132 
Age 
[Units: Years]
Median (Full Range)
 62.0 
 (24 to 82) 
 60.0 
 (30 to 82) 
 61.0 
 (24 to 82) 
Gender 
[Units: Participants]
     
Female   80   76   156 
Male   89   92   181 
Region of Enrollment [1] 
[Units: Participants]
     
Portugal   0   3   3 
Spain   19   16   35 
Ukraine   24   25   49 
Austria   16   9   25 
Russian Federation   25   24   49 
Israel   0   1   1 
Italy   8   6   14 
France   3   12   15 
Belgium   12   6   18 
Poland   30   31   61 
Romania   18   13   31 
Germany   14   22   36 
[1] Figures refer to randomized and treated participants


  Outcome Measures

1.  Primary:   Best Overall Response Rate - Independent Review Committee (IRC)   [ Time Frame: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 4 August 2006 ]

2.  Secondary:   Best Overall Response Rate (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population)   [ Time Frame: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 1 Mar 2007 ]

3.  Secondary:   Best Overall Response Rate (KRAS Mutant Population)   [ Time Frame: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 1 Mar 2007 ]

4.  Secondary:   Progression-free Survival Time   [ Time Frame: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 01 Mar 2007 ]

5.  Secondary:   Progression-free Survival Time (KRAS Wild-Type Population)   [ Time Frame: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008 ]

6.  Secondary:   Progression-free Survival Time (KRAS Mutant Population)   [ Time Frame: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008 ]

7.  Secondary:   Overall Survival Time   [ Time Frame: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008 ]

8.  Secondary:   Overall Survival Time (KRAS Wild-Type Population)   [ Time Frame: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008 ]

9.  Secondary:   Overall Survival Time (KRAS Mutant Population)   [ Time Frame: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008 ]

10.  Secondary:   Participants With No Residual Tumor After Metastatic Surgery   [ Time Frame: Time from first dose up to 30 days after the last dose of study treatment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008 ]

11.  Secondary:   Disease Control Rate (Cut Off Date 4 August 2006)   [ Time Frame: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 4 August 2006 ]

12.  Secondary:   Duration of Response   [ Time Frame: Time from first assessment of Complete Response or Partial Response to disease progression,death or last tumor assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 01 Mar 2007 ]

13.  Secondary:   Safety - Number of Patients Experiencing Any Adverse Event   [ Time Frame: time from first dose up to 30 after last dose of study treatment, reported between day of first patient dose of study treatment, 27 Jul 2005, until cut-off date 30 Nov 2008 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
A non-specific outcome measure 'Safety' was deleted from this entry in error. A replacement outcome has been created. The 'Safety' outcome refers to adverse events and these are shown in the 'Adverse Events' section.


  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Inmaculada Ollero/Clinical Trial Manager
Organization: Merck Serono
phone: +34935655433
e-mail: iollero@merck.es


Publications of Results:

Responsible Party: Merck KGaA
ClinicalTrials.gov Identifier: NCT00125034     History of Changes
Other Study ID Numbers: EMR 62202-047
First Submitted: July 28, 2005
First Posted: July 29, 2005
Results First Submitted: August 23, 2011
Results First Posted: October 4, 2011
Last Update Posted: August 7, 2014